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Abstract
Mouse plasmacytoma (PCT) can develop within 45 days when induced by a v-abl/myc replication–deficient retrovirus.
This fast-onset PCT development is always associated with trisomy of cytoband E2 ofmouse chromosome 11 (11E2).
Trisomy of 11E2 was identified as the sole aberration in all fast-onset mouse PCTs in [T38HxBALB/c]N congenic mice,
with a reciprocal translocation between chromosome X and 11 (rcpT(X;11)) (Genes Cancer 2010;1:847–858). Using
this mouse model, we have now examined the overall and individual telomere lengths in fast-onset PCTs compared
with normal B cells using two-dimensional and three-dimensional quantitative fluorescent in situ hybridization of
telomeres. We found fast-onset PCTs to have a significantly different three-dimensional telomere profile, compared
with primary B cells of wild-type littermates with and without rcpT(X;11) (P < .0001 and P = .006, respectively). Our
data also indicate for primary PCT cells, from the above mouse strain, that the translocation chromosome carrying
11E2 is the only chromosomewith telomere lengthening (P= 4× 10−16). This trend is not seen for T(X;11) in primary
B cells of control [T38HxBALB/c]N mice with the rcpT(X;11). This finding supports the concept of individual telomere
lengthening of chromosomes that are functionally important for the tumorigenic process.
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Introduction
Telomeres are DNA-protein structures at the ends of mammalian linear
chromosomes. Telomeres shorten with each cycle of cell division [1,2],
and once they reach a critically short length, in a primary cell, this cell
will normally undergo senescence [3–5]. Therefore, rapidly dividing
cells, such as stem and tumor cells, or cells surviving “crisis,” often
activate telomere lengthening mechanisms to ensure their replicative
potential [6–9]. Approximately 85% of tumor cells use telomerase, a
reverse transcriptase with an RNA template, to add telomeric repeats
to the 3′ end of parental DNA [10,11]. However, not all tumor
cells with elevated telomerase have long telomeres [12]. Approximately
15% of tumor cells use the alternative lengthening of telomeres
mechanisms to lengthen telomeres through cycles of homologous
recombination [13–16].
Telomere regulation plays a critical role in genome instability and
tumorigenesis [17–19]. Critically short telomeres and uncapped telo-
meres can trigger a series of events that lead to genomic instability and
include dynamic chromosome structure and number abnormalities
[20–22]. Dysfunctional telomeres can cause the fusion of sister chro-
matids, or the fusion of neighboring chromosomes, leading to the
formation of anaphase bridges [23]. These bridges break as the cen-
tromeres are pulled apart (so-called breakage-bridge-fusion cycles),
which results in unbalanced translocations and terminal deletions
in the daughter cells [8]. The repetitive nature of such aberrant ge-
nome remodeling cycles creates ongoing rearrangements, aneuploidy
and polyploidy, all of which are commonly found in tumor cells,
especially in tumors with complex karyotypes and high levels of cell-
to-cell heterogeneity [24–28]. However, these cycles will end if a new
telomere is acquired, usually through the cell’s activation of telomere
lengthening pathways.
Abbreviations: 2D, two-dimensional; 3D, three-dimensional; PCT, plasmacytoma;
Q-FISH, quantitative fluorescence in situ hybridization; rcpT, reciprocal translocation
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Most cases reported in the literature show mean telomere shortening
[29–31], but few studies have measured individual telomere lengths.
Quantitation of telomere length using a telomeric peptide nucleic acid
(PNA) probe was done for the first time in 1996 by Lansdorp et al.
[32]. Chromosome-specific features were proposed to control telomere
length because particular telomere lengths were associated with specific
chromosomes [33]. Telomeres on specific chromosome arms were
also found to have interallelic differences, through the use of STELA,
a polymerase chain reaction–based technique [34,35]. Chromosome-
specific telomere length changes have been identified in esophageal
cancer [36], chronic myeloid leukemia [37,38], and breast cancer
[39]. These findings in tumor cells have led to the hypothesis that there
may be chromosome-specific protective factors leading to lengthening of
certain telomeres on chromosomes “key” to the pathogenesis of the can-
cer [37,38]; however, the connection between a chromosome known to
be critical for tumorigenesis and uniquely lengthened telomeres has yet
to be made.
Mouse plasmacytoma (PCT) is a B-cell lineage tumor and the mouse
model for human Burkitt lymphoma because they both result from
c-myc activating chromosomal translocations [40] and are cytogenetically
identical. Fast-onset mouse PCTs, which can develop within 45 days, are
induced with v-abl/myc, which generates constitutive retroviral c-Myc
expression in infected preB lymphocytes [41]. A characteristic of these
tumors is the presence of chromosome 11 aberrations, which are the
only chromosomal change in fast-onset PCTs [41]. The generation of
a mouse model with a reciprocal translocation (rcpT) between chromo-
somes 11 and X, congenic [T38HxBALB/c]N with rcpT(X;11) mice,
allowed us to narrow down the affected region on chromosome 11. This
rcpT generates a very small T(X;11) translocation chromosome with
only cytoband E2 and part of E1 (Figure 1). The chromosome 11
aberration found in all fast-onset PCTs was determined to be trisomy
of the 11E2 cytoband, which contains all the genes necessary for the
accelerated tumorigenesis of these tumors [42].
We examined for the first time in mouse PCT, whether telomere
dysfunction has a role in this tumor’s development. We analyzed both
the three-dimensional (3D) telomere organization and potential two-
dimensional (2D) telomere length changes in the [T38HxBALB/c]N
mouse model, which could have been difficult because of the long
telomeres in inbred mice [29,43,44]. However, we present the consis-
tent finding, in both 2D and 3D experiments, of significantly shorter
telomeres in the fast-onset PCT cells compared with the control
[T38HxBALB/c]N mice, with or without the rcpT(X;11) trans-
location. Our unique rcpT mouse model allows us to study the meta-
phase telomere length of the T(X;11) translocation chromosome for
chromosome-specific telomere length changes that may indicate a
protective mechanism. We find the T(X;11) translocation chromo-
some, which carries the 11E2 band, critical for fast-onset PCT devel-
opment [42], has significantly longer telomeres in the fast-onset PCT
compared with the wild-type rcpT(X:11) mice. Therefore, we demon-
strate, for the first time, a connection between a chromosome key to a
tumor’s development and chromosome-specific telomere lengthening.
This finding may provide significant support for a chromosome-specific
protective mechanism used by tumor cells.
Materials and Methods
Cell Harvest, Culture, and Fixation
Primary lymphocytes were harvested from the spleens of congenic
[T38HxBALB/c]N wild-type and [T38HxBALB/c]N with rcpT
(X;11) mice [42]. Primary PCT cells were harvested from the ascites
of fast-onset PCT mice [45]. All procedures were done in accordance
with Animal Protocol 11-019 as approved by Central Animal Care
Services, University of Manitoba (Winnipeg, Manitoba, Canada).
For metaphase preparation of wild-type [T38HxBALB/c]N mice,
with or without rcpT(X;11), lymphocytes were cultured short term
(48-72 hours) in RPMI 1640 with 10% fetal bovine serum, 1%
L-glutamine, 1% sodium pyruvate, 1% penicillin-streptomycin, and
0.1% β-mercaptoethanol (Invitrogen/Gibco, Burlington, Ontario,
Canada) with lipopolysaccharide at a concentration of 10 μg/ml at
37°C in a humidified atmosphere and 5% CO2. Cells were maintained
at a density of around 106 cells/ml.
2D Chromosome and 3D Nuclei Fixation
Primary cells from the mice or cell culture were spun down at 200g
for 10 minutes at room temperature. For 3D fixation [24,46,47], the
pellet was resuspended in 5 ml of 0.075 M KCl for 10 minutes at room
temperature and then overlaid with 1 ml of fresh 3:1 methanol-to-
acetic acid fixative and inverted gently. Twice more, the cells were
spun down at 200g for 10 minutes at room temperature and re-
suspended in 2 ml of fixative. Thirty microliters of this solution was
gently placed on a slide, and the remainder was stored at −20°C. For
2D fixation, the initial pellet was resuspended in 5 ml of 0.075 ml for
30 minutes at room temperature, spun down at 200g for 10 minutes
Figure 1. Graphical illustration of the chromosomal constitution of
chromosomes 11 in the (BALB/cxT38H) F1 N backcross genera-
tion mouse. Chromosome (Chr) 11 with the breakpoint T38H in
the telomeric cytoband 11E1 (brown), whereas the breakpoint in
Chr X is located in the centromeric A2 band. The cytoband 11E2
is red. The reciprocally translocated T(11;X) chromosome resulted
from the fusion of the ABCD bands of Chr 11 proximal to the T38H
breakpoint with the centromeric A2 band of Chr X. The T(X;11)
chromosome was generated by the translocation of the X-derived
A2 subband onto the 11E1 cytoband of Chr 11. The final, definitive
version of this figure has been published in Genes Cancer. 2010;
1(8):847–858. SAGE Publications Ltd. All rights reserved. © http://
online.sagepub.com.
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at room temperature and then the pellet underwent drop fixation
with 3:1 methanol-to-acetic acid fixative [48]. For statistical signifi-
cance, at least 20 metaphases with nonoverlapping chromosomes and
30 nuclei were examined in three independent experiments for each
mouse type [24,27].
Telomere Quantitative Fluorescence In Situ Hybridization
Telomere quantitative fluorescence in situ hybridization (Q-FISH)
was performed on both 2D metaphases and 3D interphase nuclei
with a PNA probe for telomeres purchased from DAKO (Glostrup,
Denmark). In brief for the 2D telomere hybridization, the slides were
fixed in fresh 3.7% formaldehyde/1× PBS, washed in 1× PBS, followed
by a pepsin/HCl treatment and a second fixation. After ethanol
dehydrations, the telomere PNA probe was applied, sealed onto the
slide with rubber cement, and underwent a 3-minute denaturation at
80°C and 2-hour hybridization at 30°C using a Hybrite (Vysis; Abbott
Diagnostics, Des Plains, IL). Then the slides were washed in 70%
formamide/10 mM Tris at pH 7.4, 1× PBS, 0.1× SSC at 55°C, and
2× SSC/0.05% Tween 20. The cells were then counterstained with
4′6′-diamidino-2-phenylindole (DAPI), dehydrated, and mounted in
Vectashield (Vector Laboratories, Burlington, Ontario, Canada). For
the 3D telomere hybridization, briefly, the slides were fixed in 3.7%
formaldehyde/1× PBS, incubated in 0.5% Triton X, followed by an
hour incubation in glycerol and freeze-thaw treatment with liquid
nitrogen. After 1× PBS washed and a HCl incubation, the slides were
equilibrated in 70% formamide/2× SSC at pH 7.0. Then the slides un-
derwent the same denaturation and hybridization, subsequent washes,
staining, and mounting procedure as in the 2D fixation protocol.
In 3D, very short telomeres are defined as signals at a relative fluo-
rescent intensity from 0 to 10,000 and short telomeres are defined as
signals at a relative fluorescent intensity from 10,000 to 20,000. In 2D,
very short telomeres are defined as signals at a relative fluorescent in-
tensity from 0 to 30,000 and short telomeres are defined as signals at a
relative fluorescent intensity from 30,000 to 50,000.
Image Acquisition
2D and 3D imaging and acquisition were performed using an
AxioImager Z2 microscope (Carl Zeiss, Toronto, Canada), an AxioCam
HR charge-coupled device (Carl Zeiss), and Zeiss AxioVision 4.8 soft-
ware (Carl Zeiss). A 63×/1.4 oil objective lens (Carl Zeiss) was used with
a DAPI filter, for detection of nuclear DNA staining, and a cyanine 3
filter, for detection of the telomere PNA probe signals. All metaphases
images were taken at the same exposure time, and tricolor beads were
used for standardization; the same protocol was used for all imaging
of all interphase nuclei. For 3D imaging, 80 z stacks at 200 nm each,
with x, y = 102 nm, z = 200 nm were acquired. The acquired images
were deconvolved using the constrained iterative algorithm [49]. To
quantitatively analyze the metaphase telomere signals, Case Data
Manager 4.0 software (Applied Spectral Imaging, Migdal HaEmek,
Israel) for PC was used. TeloView software [50] was used to quantita-
tively analyze the 3D interphase telomere signals.
Statistical Analysis
Statistical analysis was done to compare the percentage of interphase
telomeric signals at a certain intensity, using bins at an interval of 1000,
from 0 to 225,000. An analysis was also done on the percentage of
metaphase telomere signals at a certain intensity, using bins at an inter-
val of 5000, from 0 to 195,000. Using a χ2 test, the telomere signal
distribution was compared between the fast-onset PCT and the wild-
type mice, with and without rcpT(X;11), and between the two types of
wild-type mice. One threshold was set at the 50th percentile or median.
P < .01 is considered significant.
Statistical analysis was also done to compare the telomere length of
translocation chromosome T(X;11) to the telomere length of all other
chromosomes. This was done using a Kolmogorov-Smirnov test in
both the fast-onset PCT and the [T38HxBALB/c]N with rcpT(X;11)
wild-type mice. P < .001 is considered significant.
Results
3D Telomere Organization
To investigate the 3D telomere organization in wild-type mice, with
or without rcpT(X;11), and in fast-onset PCTs of the same mice, 3D
Q-FISH was done with a telomere-PNA probe. This approach pre-
serves the 3D nuclear architecture of the cells and specifically labels
interphase telomeres in the whole cell population. After acquisition
and constrained iterative deconvolution, all 3D interphase nuclei were
analyzed with TeloView to determine the number of telomeric signals
per cell and their intensity. The signal intensity correlates to the length
of the telomere [51].
Figure 2 (A-C) shows a representative example of the 3D telomere
organization in an interphase nucleus from the [T38HxBALB/c]N
wild-type and [T38HxBALB/c]N with rcpT(X;11) control mice and
the fast-onset PCT mouse. The telomeric signals were visibly smaller
in the fast-onset PCT nuclei than in controls. The results from three
independent experiments for each mouse type were combined, and
the telomeric profiles of the three mice were compared. Figure 2D is
a scatterplot that illustrates the number of telomere signals at a specific
intensity. The distribution of telomeres is shown for intensities in the
range of 0 to 160,000. As expected, 3D nuclei of the wild-type mice,
whether carrying the rcpT(X;11) or not, have a similar telomere pro-
file and are not significantly different, P = .3 (as determined by a χ2
test with P < .01 considered significant). The fast-onset PCT nuclei
have many more low-intensity or very short telomeres (Materials and
Methods), and their telomere profile is significantly different from
both wild-type mice with or without rcpT(X;11) (P < .0001 and P =
.006, respectively).
2D Telomere Length
To determine the length of individual telomeres on all chromosomes
in wild-type mice, with or without rcpT(X;11), and in fast-onset PCTs
of the same mice, 2D Q-FISH was done with a telomere-PNA probe.
This method hybridizes metaphases with a specific probe for labeling all
telomeric signals. After acquisition, all metaphase spreads were analyzed
with Case Data Manager 4.0 to determine the intensity of each telo-
mere signal, which correlates to the length of the telomere [51].
Figure 3 (A-C ) illustrates an example of the telomeric signals in
a metaphase spread from the [T38HxBALB/c]N wild-type and
[T38HxBALB/c]N with rcpT(X;11) control mice and in fast-onset
PCTs of [T38HxBALB/c]N mice. As indicated with a circle, the small
T(X;11) translocation chromosome is easy to identify based on size
alone (see also Figure 1). The results from three independent experi-
ments for each mouse type were combined, and the telomere lengths
of the three mice were compared. Figure 3D is a scatterplot that illus-
trates the percentage of telomere signals at a specific intensity. The
distribution of telomeres is shown for intensities in the range of 0
to 160,000. As in the 3D interphase study, chromosomes from wild-
type mice, with or without rcpT(X;11), have a similar distribution of
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telomere lengths and are not significantly different, P = 1.0 (as deter-
mined by a χ2 test with P < .01 considered significant). The chromo-
somes of fast-onset PCTs have more lower intensity or very short
telomeres (see Materials and Methods), and their telomere length
distribution is significantly different from [T38HxBALB/c]N mice,
carrying rcpT(X;11) or not (P < .0001 for both mouse types).
The graphs in Figure 4 (A and B) compare the telomere length of
translocation chromosome T(X;11) to the telomere length of the rest
of the chromosomes for the [T38HxBALB/c]N with rcpT(X;11)
(Figure 4A) and fast-onset PCT mice (Figure 4B). In the tumor-free
control mouse, [T38HxBALB/c]N with rcpT(X;11), the telomeres of
the T(X;11) translocation chromosome do not have a significantly
different length from those of the rest of the chromosomes, P = .006
(as determined by a Kolmogorov-Smirnov test with P < .001 consid-
ered significant). However, in the fast-onset PCT mouse, the telomeres
of the T(X;11) translocation chromosome, carrying 11E2, are signifi-
cantly longer than those of the rest of the chromosomes (P = 4 × 10−16).
Discussion
Although short telomeres are a common finding in many tumor cells,
3D telomere organization and telomere length have not been previ-
ously examined in mouse PCT. Our mouse model offers a unique
opportunity to study chromosome-specific telomere length regula-
tion because its rcpT places only the genes necessary for accelerated
Figure 2. 3D telomere organization in interphase nuclei. (A) Nucleus from the [T38HxBALB/c]N wild-type mouse. (B) Nucleus from the
[T38HxBALB/c]N with rcpT(X;11) mouse. (C) Nucleus from the fast-onset PCT mouse. (D) Comparison of the telomeric profile of the three
mouse types. The intensity correlates to the telomere length. The fast-onset PCT nuclei (black) have significantly more very short telomeres
(see Materials and Methods) than the [T38HxBALB/c]N wild-type (red) and the [T38HxBALB/c]N with rcpT(X;11) (blue) mouse (P= .006 and
P < .0001, respectively).
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tumorigenesis on a single easily identifiable chromosome, the T(X:11)
translocation chromosome [42]. Because we also studied control
wild-type mice, with and without the rcpT(X;11) translocation, we
are able to make conclusions about tumor-specific telomere changes.
Inbred mice can pose a problem for telomere studies because they nor-
mally have long telomeres [43,44]. When comparing generations of
telomerase knockout mice, significant decreases in telomere size were
not seen until generation 6 [29]. However, we present similar results
regarding significant alterations in telomere length within the identical
mouse strain/generation. Using two complementary approaches, 2D
and 3D telomere Q-FISH, we identified significant telomere length
changes during fast-onset PCT development.
We found that the 3D interphase nuclei of fast-onset PCT mice
had visibly and significantly shorter telomeres compared with the
wild-type mice, with or without the rcpT(X;11) translocation (P =
.006 and P < .0001, respectively; Figure 2). We also determined that,
overall, the telomeres on the metaphase chromosomes of fast-onset
PCT mice were significantly shorter than in wild-type mice (P <
.0001 for both wild-type mice; Figure 3). With a 3D interphase
nuclei study, features of every cell can be analyzed, whereas only
Figure 3. 2D telomere length in metaphase chromosomes. (A) Metaphase spread from the [T38HxBALB/c]N wild-type mouse. (B) Meta-
phase spread from the [T38HxBALB/c]N with rcpT(X;11) mouse. The translocation chromosome T(X;11) is circled and enlarged. (C) Meta-
phase spread from the fast-onset PCT mouse. The translocation chromosome T(X;11) is circled and enlarged. Very short telomeres are
marked with an asterisk. (D) Comparison of the telomeric length distribution of the three mouse types. The intensity correlates to the
telomere length. The fast-onset PCT nuclei (black) have significantly more very short telomeres (see Materials and Methods) than the
[T38HxBALB/c]N wild-type (red) and the [T38HxBALB/c]N with rcpT(X;11) (blue) mouse (P < .0001 for both mouse types).
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metaphases can be examined in a 2D study; therefore, a 3D analysis
is more exact, and although it is complemented by the results of a
2D study, it cannot be replaced by solely a 2D analysis. By exam-
ining the telomeres of the T(X;11) translocation chromosome com-
pared with all other telomeres, we identified that T(X;11) telomeres
were significantly longer than telomeres on all other chromosomes in
the fast-onset PCT cells (P = 4 × 10−16) but not significantly different
in the tumor-free [T38HxBALB/c]N with rcpT(X;11) cells (P = .006;
Figure 4).
It is now apparent that gene expression depends on more than
the underlying DNA sequence. Therefore, it is important to study
the nuclear architecture of cells, such as telomeres, because this may
lead to new diagnostic and treatment options. Multiple studies have
identified changes in the 3D telomere organization in disease states
[25,46,52–56]. For example, myelodysplastic syndrome and acute
myeloid leukemia are two distinct disorders, but part of the same dis-
ease spectrum because some cases of myelodysplastic syndrome will
transform into acute myeloid leukemia [57]. Unique 3D telomeric
signatures have been identified for normal versus tumor cells, which
can aid in the diagnosis of patients [56].
Our findings in fast-onset mouse PCTs identify a tumor for which
there is a unique 3D telomere profile compared with control cells
(Figure 2D). More short telomeres were observed in the fast-onset
PCT mouse compared with the control mice. This is consistent with
our mouse model because a fast-developing tumor, with 45 days of
latency period, exhibits a high rate of cell division and consequently
displays enhanced telomere shortening, as we observed in this study.
Telomerase and alternative lengthening of telomeres, the mecha-
nisms by which tumor cells lengthen telomeres to avoid cell senes-
cence from critically short telomeres, are well described. However,
chromosome-specific telomere alterations are not as well understood.
In 2009, Samassekou et al. [37] identified chromosome arms, in
chronic myeloid leukemia, that consistently had longer telomeres
(18p, Xp, 1p, and 14p) and ones that consistently had shorter telomeres
(20q, 21p, 21q, and 9q) than the rest of the chromosomes. In their
most recent study, Samassekou et al. [38] found that Xp and 5p had
significantly longer telomeres at a higher frequency in chronic myeloid
leukemia than in healthy cells. They propose that the presence of
only one X chromosome may drive the cell to protect it from telomere
shortening. They also suggest that because the gene encoding the re-
verse transcriptase component of telomerase is located on 5p, the cell
may lengthen its telomeres to regulate the gene. These findings have
led them to propose that tumor cells may protect key genes responsi-
ble for their tumorigenesis through a chromosome-specific telomere
lengthening mechanism.
Our study supports this hypothesis and goes one step further to
prove its potential validity. In fast-onset PCTs, the T(X;11) trans-
location chromosome contains all the genes necessary for the tumor’s
accelerated development in cytoband 11E2 [42], and the trisomy of
11E2 represents the only aberration; therefore, it is probably the
most important chromosome to protect. Our findings indicate that
the T(X;11) translocation chromosome has significantly longer telo-
meres than all other chromosomes in the fast-onset PCT cells but not
in B cells of the tumor-free [T38HxBALB/c]N mice with rcpT
(X:11). Therefore, these findings illustrate a chromosome-specific
protective mechanism and suggest a functional tumor-dependent
requirement for its selective protection.
Mouse PCT is cytogenetically identical to human Burkitt lymphoma
and therefore is an excellent mouse model of the cancer. The genes
within mouse chromosome 11E2 are syntenic to rat chromosome
10q32 [58] and human chromosome 17q25 [59]. This region is dupli-
cated, translocated and amplified in many lymphoid and nonlymphoid
tumor types such as human acute myeloid leukemia, breast, ovarian,
and thyroid cancers [59–62]. Therefore, the chromosome-specific telo-
mere length increase observed on translocation chromosome T(X;11)
in fast-onset mouse PCT may also occur on the human chromosome
17 due to the functional relevance of 17q25 for tumor development
and warrants further investigation in an independent study.
To examine whether telomere dysfunction has an important role
in mouse PCT, we used the techniques of 2D and 3D telomere
Q-FISH to study the tumorigenic changes associated with fast-onset
mouse PCT in interphase telomere organization and metaphase telo-
mere length. We found selective telomere lengthening and aberrant
3D telomere organization in the fast-onset PCTs. Therefore, we
provide significant support for a chromosome-specific protective
mechanism that has a functional tumor-dependent requirement for
its selective protection.
Figure 4. Comparison of the length of the T(X;11) translocation
chromosome. (A) In the [T38HxBALB/c]N with rcpT(X;11) mouse,
telomeres of the T(X;11) translocation chromosome (black) are not
significantly longer than those of the other chromosomes (gray)
(P = .006). (B) In the fast-onset PCT mouse, the telomeres of the
T(X;11) translocation chromosome (black) are significantly longer
than the other chromosomes (gray) (P = 4 × 10−16).
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